抗菌药物抗药性监测市场－全球产业规模、份额、趋势、机会及预测（按解决方案、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球抗生素抗药性监测市场预计将从 2025 年的 65.4 亿美元成长到 2031 年的 92.7 亿美元，复合年增长率为 5.98%。

该领域包括专门的诊断设备和软体平台，旨在系统地追踪和分析病原体对抗菌药物的反应。推动这一成长的关键因素包括：迫切需要应对多重抗药性细菌的日益增多，以及全球严格执行抗菌药物管理计画。此外，政府积极采取措施并投入资金，旨在加强检查室基础设施建设并确保数据相容性，这也加速了这些关键监测系统在医疗网路中的应用。

儘管取得了这些进展，但实施和维护先进监测技术的高成本仍然是一大障碍，阻碍了其在资源匮乏地区的广泛应用。这种资金限制往往阻碍了缺乏足够技术基础设施的发展中地区广泛采用自动化报告功能。世界卫生组织（世卫组织）表示，到2025年，已有127个国家正式加入全球抗菌药物抗药性和使用监测系统（GAMURS），以支持标准化监测倡议，但成本障碍仍然是普遍实施的一大挑战。

市场驱动因素

多重抗药性感染疾病的日益普遍是全球抗菌药物抗药性监测市场的主要驱动因素，也因此迫切需要扩展诊断能力。随着病原体对标准疗法产生抗药性的速度加快，医疗系统面临着实施能够即时检测抗药性模式的先进监测框架的压力。这种日益严重的生物威胁推动了对高通量系统的需求，以支持经验性治疗和控制策略。根据2024年9月发表在《采血针》上的一项系统性分析，预计2025年至2050年间，细菌抗菌药物抗药性将导致全球超过3900万人直接死亡，这迫使诊断技术开发商优先开发能够识别新型抗药性标誌物的技术，以减轻预计的死亡负担。

第二个关键驱动因素是公共和私人部门加大对抗菌素抗药性监测和基础设施的投入，这直接解决了建构全面监测网路的高成本。各国政府和国际组织正积极资助检查室现代化改造，以填补人类、动物和环境健康的数据空白。例如，英国政府于2024年5月宣布了一项8,500万英镑的资助计划，用于支持国际合作，包括加强加勒比海和非洲的监测工作。儘管进行了这些投资，挑战依然存在。全球老化联盟2024年2月发布的报告显示，在分析的11个高所得国家中，只有4个国家定期监测水质中的抗菌素抗药性基因，显示环境监测解决方案存在持续的市场机会。

市场挑战

实施和维护诊断技术所需的大量资金投入是限制抗菌素抗药性监测市场成长的主要因素。这一成本壁垒严重限制了自动化报告系统的普及，尤其是在医疗预算有限、难以资金筹措数位基础设施的地区。因此，开发中国家的许多医疗机构仍然沿用人工数据收集方法，而不是采用数位追踪平台，这实际上限制了诊断设备製造商的潜在市场规模。

此外，难以获得必要的预算拨款直接阻碍了全球监测网路的扩充性。当医疗机构无法承担初始资本支出和持续营运成本时，供应商在高负担地区的需求就会下降。世界卫生组织（世卫组织）指出，到2024年，只有11%的国家会拨出专案财政资源用于实施国家抗菌素抗药性计画。这种专款的匮乏导致全球潜在市场的大部分未能开发，从而阻碍了标准化监测设备的广泛应用。

市场趋势

全基因测序(WGS) 的广泛应用正在革新全球抗菌药物抗药性监测市场，使其能够对病原体进行超越传统表型方法的精准基因表征。这项技术进步使公共卫生网路能够快速识别感染丛集，追踪多重抗药性克隆的演变，并准确区分復发和再感染。随着实验室越来越依赖基因组数据来指南防治策略，分子诊断正成为国家监测基础设施的标准。欧洲疾病预防控制中心 (ECDC) 2025 年 11 月发布的一份报告显示，在 26 个国家的参与实验室中，84% 的实验室报告称使用包括 PCR 和全基因组定序在内的分子方法来筛选分离株，以进行更高级的抗菌药物敏感性测试。

同时，人工智慧 (AI) 和机器学习的融合正在彻底改变监测资料的处理和预测分析方式。这些先进的计算工具能够分析来自各种来源的庞大而复杂的数据集，有助于及早发现新出现的抗药性热点，并优化经验性处方实践。透过自动识别抗药性模式，人工智慧驱动的平台显着缩短了产生可操作见解所需的时间，从而刺激了对智慧监测生态系统的大量投资。例如，根据 Alliance News 2025 年 11 月报道，葛兰素史克 (GSK) 与倡议)的战略合作伙伴关係已承诺资金筹措约 50 个科研岗位，这些岗位专注于利用先进的缓解和超级计算技术追踪和感染疾病。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球抗菌素抗药性监测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依解决方案分类（诊断试剂盒、诊断系统、监控软体、服务）
  • 按应用领域（临床诊断、公共卫生监测、其他应用）
  • 依最终使用者（医院/诊所、研究/学术机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美抗菌素抗药性监测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲抗菌素抗药性监测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区抗菌素抗药性监测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲抗菌素抗药性监测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲抗菌素抗药性监测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球抗菌素抗药性监测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Luminex Corporation（DiaSorin）
• Thermo Fisher Scientific Inc
• Accelerate Diagnostics, Inc.
• Liofilchem SrI
• Becton, Dickinson, and Company
• Biomerieux Inc.
• Bruker Corp.
• Danaher Corporation
• Merck KgaA
• Abbott Laboratories Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Antimicrobial Resistance Surveillance Market is projected to expand from USD 6.54 billion in 2025 to USD 9.27 billion by 2031, reflecting a compound annual growth rate of 5.98%. This sector comprises specialized diagnostic instruments and software platforms designed to systematically track and analyze how pathogens respond to antimicrobial drugs. The primary forces propelling this growth include the critical need to address the rising prevalence of multidrug-resistant organisms and the global enforcement of strict antimicrobial stewardship programs. Additionally, significant government efforts and funding aimed at bolstering laboratory infrastructure and ensuring data compatibility are actively speeding up the adoption of these essential monitoring systems within healthcare networks.

Despite this progress, major hurdles exist due to the high costs associated with installing and maintaining advanced surveillance technologies, which hinders adoption in resource-limited settings. This financial constraint frequently restricts the spread of automated reporting capabilities in developing regions that lack adequate technical infrastructure. According to the World Health Organization, 127 countries had formally joined the Global Antimicrobial Resistance and Use Surveillance System by 2025 to support standardized monitoring initiatives, yet the cost barrier continues to challenge universal implementation.

Market Driver

The escalating prevalence of multi-drug resistant infections acts as the main catalyst for the Global Antimicrobial Resistance Surveillance Market, creating an urgent need to expand diagnostic capabilities. As pathogens evolve to resist standard treatments more rapidly, healthcare systems are forced to implement advanced monitoring frameworks capable of detecting resistance patterns in real time. This rise in biological threats fuels the demand for high-throughput systems that support empirical therapy and containment strategies. According to The Lancet's September 2024 systematic analysis, bacterial antimicrobial resistance is forecast to cause over 39 million direct deaths globally between 2025 and 2050, compelling diagnostic developers to prioritize technologies that identify emerging resistance markers to reduce this anticipated mortality burden.

A second critical driver is the increase in public and private funding for AMR research and infrastructure, which directly addresses the high costs of building comprehensive surveillance networks. Governments and international organizations are actively financing the modernization of laboratories to bridge data gaps across human, animal, and environmental health sectors. For instance, the UK Government announced in May 2024 a financial package of £85 million to bolster international efforts, including surveillance strengthening in the Caribbean and Africa. Despite such investments, gaps remain; the Global Coalition on Aging reported in February 2024 that only four out of eleven analyzed high-income countries regularly monitored water for antimicrobial resistance genes, indicating a sustained market opportunity for environmental surveillance solutions.

Market Challenge

The significant financial investment needed to install and maintain diagnostic technologies acts as a major restraint on the antimicrobial resistance surveillance market's growth. This cost barrier severely restricts the uptake of automated reporting systems, especially in regions with limited healthcare budgets where funding digital infrastructure is difficult. As a result, many healthcare facilities in developing economies persist in using manual data collection methods instead of integrating digital tracking platforms, which effectively limits the potential market size for diagnostic manufacturers.

Furthermore, the inability to secure necessary budget allocations directly impedes the scalability of global surveillance networks. When medical institutions are unable to afford initial capital expenditures or ongoing operational costs, vendors experience reduced demand in high-burden regions. According to the World Health Organization, only 11 percent of countries had allocated dedicated financial resources to implement their national antimicrobial resistance action plans in 2024. This lack of specific financing leaves a large portion of the potential global market untapped, thereby stalling the widespread deployment of standardized monitoring instruments.

Market Trends

The widespread adoption of Whole Genome Sequencing (WGS) is significantly transforming the Global Antimicrobial Resistance Surveillance Market by allowing for precise genetic characterization of pathogens beyond traditional phenotypic methods. This technological advancement enables public health networks to quickly identify transmission clusters, track the evolution of multi-drug resistant clones, and accurately distinguish between relapse and reinfection. As laboratories increasingly rely on genomic data to guide containment strategies, molecular diagnostics are becoming a standard element of national monitoring infrastructures. According to the European Centre for Disease Prevention and Control's November 2025 report, 84 percent of participating laboratories across 26 countries reported using molecular methods, including PCR and whole-genome sequencing, to select isolates for advanced antimicrobial susceptibility testing.

Concurrently, the integration of Artificial Intelligence and Machine Learning is revolutionizing how surveillance data is processed and used for predictive analytics. These advanced computational tools analyze vast and complex datasets from various sources, facilitating the early detection of emerging resistance hotspots and the optimization of empirical prescribing practices. By automating the identification of resistance patterns, AI-driven platforms drastically reduce the time needed to generate actionable insights, attracting significant investment into smart surveillance ecosystems. For example, Alliance News reported in November 2025 that a strategic partnership between GSK and the Fleming Initiative committed £45 million to fund approximately 50 scientific roles focused on using advanced AI and supercomputing to track and mitigate drug-resistant infections.

Key Market Players

• Luminex Corporation (DiaSorin)
• Thermo Fisher Scientific Inc
• Accelerate Diagnostics, Inc.
• Liofilchem S.r.I.
• Becton, Dickinson, and Company
• Biomerieux Inc.
• Bruker Corp.
• Danaher Corporation
• Merck KgaA
• Abbott Laboratories Inc.

Report Scope

In this report, the Global Antimicrobial Resistance Surveillance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimicrobial Resistance Surveillance Market, By Solution

• Diagnostic kits
• Diagnostic systems
• Surveillance software
• Services

Antimicrobial Resistance Surveillance Market, By Application

• Clinical Diagnostics
• Public Health Surveillance
• Other Applications

Antimicrobial Resistance Surveillance Market, By End User

• Hospitals & Clinics
• Research & Academic Institutes
• Others

Antimicrobial Resistance Surveillance Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimicrobial Resistance Surveillance Market.

Available Customizations:

Global Antimicrobial Resistance Surveillance Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antimicrobial Resistance Surveillance Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Solution (Diagnostic kits, Diagnostic systems, Surveillance software, Services)
  • 5.2.2. By Application (Clinical Diagnostics, Public Health Surveillance, Other Applications)
  • 5.2.3. By End User (Hospitals & Clinics, Research & Academic Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Antimicrobial Resistance Surveillance Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Solution
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antimicrobial Resistance Surveillance Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Solution
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Antimicrobial Resistance Surveillance Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Solution
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Antimicrobial Resistance Surveillance Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Solution
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Antimicrobial Resistance Surveillance Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Solution
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antimicrobial Resistance Surveillance Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Solution
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Antimicrobial Resistance Surveillance Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Solution
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Antimicrobial Resistance Surveillance Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Solution
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Antimicrobial Resistance Surveillance Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Solution
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Antimicrobial Resistance Surveillance Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Solution
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Antimicrobial Resistance Surveillance Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Solution
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antimicrobial Resistance Surveillance Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Solution
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Antimicrobial Resistance Surveillance Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Solution
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Antimicrobial Resistance Surveillance Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Solution
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Antimicrobial Resistance Surveillance Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Solution
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Antimicrobial Resistance Surveillance Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Solution
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Antimicrobial Resistance Surveillance Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Solution
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antimicrobial Resistance Surveillance Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Solution
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Antimicrobial Resistance Surveillance Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Solution
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Antimicrobial Resistance Surveillance Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Solution
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Antimicrobial Resistance Surveillance Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Solution
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antimicrobial Resistance Surveillance Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Solution
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Antimicrobial Resistance Surveillance Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Solution
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Antimicrobial Resistance Surveillance Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Solution
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antimicrobial Resistance Surveillance Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Luminex Corporation (DiaSorin)
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc
• 15.3. Accelerate Diagnostics, Inc.
• 15.4. Liofilchem S.r.I.
• 15.5. Becton, Dickinson, and Company
• 15.6. Biomerieux Inc.
• 15.7. Bruker Corp.
• 15.8. Danaher Corporation
• 15.9. Merck KgaA
• 15.10. Abbott Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer